Cedar Rapids Oncology Project (CROP) has provided an active cancer research program to Eastern Iowa since 1985. A commitment to community based cancer research led to affiliation with the North Central Cancer Treatment Group (NICCTG). CROP is now joined in this application by the Regional Oncology Program (ROP) of Moline, Illinois. A cohesive multidisciplinary team of cancer professionals has been assembled. The Cedar Rapids component includes Mercy Medical Center, St. Luke's Hospital, the Hall Radiation Center, and Oncology Associates. The Moline component is comprised of United Hospitals and the Oncology Section of Medical Arts Associates. All oncology specialities in both communities are actively participating with this research effort. Modern comprehensive diagnostic and treatment facilities are available. CROP and ROP provide cancer care to a population base of 500,000 people in Eastern Iowa and Western Illinois. It is estimated that CROP components see 80% of newly diagnosed patients from this areas for a total of 1,500- 1,600 new cancer patients annually. Enthusiastic local support and strong assistance from NCCTG has resulted in increasing accrual and major participation with NCCTG and ECOG research studies. NCCTG is identified as primary and ECOG as a secondary research base. 75 cancer treatment patients were entered in 1988. Joined now by the ROP of Moline, 43 cancer treatment and 120 cancer control entries were made January to June 1989. It is projected that 100 cancer treatment and 250 cancer control patients will be entered the first year of CCOP participation. Expansion is expected to 120 cancer treatment and 300 cancer control entries by year 3 of the grant. Cancer control accrual has substantially increase over the past six months with case entries totaling 16 NCI credits January to June 1989. CROP components are also active with community based cancer control activities, and with the assistance of the ROP, and the availability of new studies, CROP will be able to meet the requirements of the CCOP RFA. A detailed organizational structure and data management plan is submitted. These systems are presently operational and effective. Quality control has been evidenced through external audit, and by no major violations, and by an ineligibility rate of only 1.5% since 1985. A three year budget of $584,572 is requested as all direct support without indirect funding. Direct costs indicate the intensive participation of physicians, nurses, and data managers necessary to provide this research effort, and especially the extensive nursing and data manager commitment necessary to sustain an active cancer control program. CROP has documented its ability to initiate and expand an effective multidisciplinary cancer research program. With CCOP funding, greater and more productive efforts can be made to improve cancer care in the heartland.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Cooperative Clinical Research--Cooperative Agreements (U10)
Project #
5U10CA052352-03
Application #
3558897
Study Section
Special Emphasis Panel (SRC (54))
Project Start
1990-09-15
Project End
1993-05-31
Budget Start
1992-06-01
Budget End
1993-05-31
Support Year
3
Fiscal Year
1992
Total Cost
Indirect Cost
Name
Cedar Rapids Oncology Project
Department
Type
DUNS #
186618497
City
Cedar Rapids
State
IA
Country
United States
Zip Code
52403
Barton, Debra L; Sloan, Jeff A; Shuster, Lynne T et al. (2018) Evaluating the efficacy of vaginal dehydroepiandosterone for vaginal symptoms in postmenopausal cancer survivors: NCCTG N10C1 (Alliance). Support Care Cancer 26:643-650
Sio, Terence T; Atherton, Pamela J; Birckhead, Brandon J et al. (2016) Repeated measures analyses of dermatitis symptom evolution in breast cancer patients receiving radiotherapy in a phase 3 randomized trial of mometasone furoate vs placebo (N06C4 [alliance]). Support Care Cancer 24:3847-55
Pachman, Deirdre R; Qin, Rui; Seisler, Drew et al. (2016) Comparison of oxaliplatin and paclitaxel-induced neuropathy (Alliance A151505). Support Care Cancer 24:5059-5068
Van Loon, Katherine; Espinoza, Anne M; Fogelman, David R et al. (2014) Should combination chemotherapy serve as the backbone in clinical trials of advanced pancreatic cancer? A pooled analysis of phase II trials of gemcitabine-containing doublets plus bevacizumab. Pancreas 43:343-9
Leal, Alexis D; Qin, Rui; Atherton, Pamela J et al. (2014) North Central Cancer Treatment Group/Alliance trial N08CA-the use of glutathione for prevention of paclitaxel/carboplatin-induced peripheral neuropathy: a phase 3 randomized, double-blind, placebo-controlled study. Cancer 120:1890-7
Province, M A; Goetz, M P; Brauch, H et al. (2014) CYP2D6 genotype and adjuvant tamoxifen: meta-analysis of heterogeneous study populations. Clin Pharmacol Ther 95:216-27
Galanis, Evanthia; Anderson, S Keith; Lafky, Jackie M et al. (2013) Phase II study of bevacizumab in combination with sorafenib in recurrent glioblastoma (N0776): a north central cancer treatment group trial. Clin Cancer Res 19:4816-23
Brown, Lindsay C; Atherton, Pamela J; Neben-Wittich, Michelle A et al. (2013) Assessment of long-term rectal function in patients who received pelvic radiotherapy: a pooled North Central Cancer Treatment Group trial analysis, N09C1. Support Care Cancer 21:2869-77
Kottschade, Lisa A; Suman, Vera J; Perez, Domingo G et al. (2013) A randomized phase 2 study of temozolomide and bevacizumab or nab-paclitaxel, carboplatin, and bevacizumab in patients with unresectable stage IV melanoma : a North Central Cancer Treatment Group study, N0775. Cancer 119:586-92
Lavoie Smith, Ellen M; Barton, Debra L; Qin, Rui et al. (2013) Assessing patient-reported peripheral neuropathy: the reliability and validity of the European Organization for Research and Treatment of Cancer QLQ-CIPN20 Questionnaire. Qual Life Res 22:2787-99

Showing the most recent 10 out of 120 publications